CC-115

N/A

Report date: 2026/03/12 20:00:16
NME

Base Information

Drug NameCC-115
Drug Alias NameCC-115
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsDNA-dependent protein kinase inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2DNA-dependent protein kinase
Therapy Area/IndicationsNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyFrance +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesCelgene Corp
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsGlioblastoma
Inactive IndicationsNeoplasm MetastasisSquamous Cell Carcinoma of Head and NeckSarcoma, Ewing +[4] 

Other Information

ATC CodeN/A
Related LinksN/A